Post-Approval Safety Monitoring Requirements for Orphan Drugs
Post-Approval Safety Monitoring Requirements for Orphan Drugs Ensuring Safety After Approval: Monitoring Obligations for Orphan Drugs Introduction: Why Post-Marketing Safety is Critical in Rare Diseases Orphan drugs offer hope for patients with rare diseases, but their approval often comes with limited pre-market safety data due to small trial populations. This makes post-approval safety monitoring essential….
Read More “Post-Approval Safety Monitoring Requirements for Orphan Drugs” »